Related Experiment Video
Updated: Jun 24, 2026

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
Published on: July 3, 2025
Expression and prognostic value of activating transcription factor 2 (ATF2) and its phosphorylated form in mammary
Stefan Knippen1, Thomas Löning, Volkmar Müller
1Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Background:
The transcription factor ATF2 is overexpressed in various tumors, but its role in breast cancer is still not understood.
Materials And Methods:
In a study of mammary carcinomas, the expression of ATF2 and its phosphorylated active forms was analyzed by Western blot analysis (WB; pThr69/pThr71-ATF2, n=134) and immunohistochemistry (IHC; p-ATF2-Thr6, n=110). Results were correlated with histological and clinical data, survival data, expression of ERK1/2 and two matrix metalloproteinases.
Results:
Patients with high ATF2 expression as detected by WB had a significantly shorter overall survival (p = 0.038). This tendency was corroborated by IHC. In contrast, high p-ATF2 expression as found by WB correlated significantly with a well-differentiated phenotype, but not with prognosis. Immunohistochemically detected p-ATF2 overexpression was even associated with prolonged survival (p = 0.047).
Conclusion:
Although high ATF2 expression is associated with a poor prognosis, our data do not point to an oncogenic role of active p-ATF2 in mammary carcinomas.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Master Transcription Regulators
MAPK Signaling Cascades
Abnormal Proliferation
TGF - β Signaling Pathway
